Reason for request
Extension of the indication
Clinical Benefit
Clinical Added Value
| moderate |
Given the efficacy of VOTUBIA (everolimus) in reducing renal angiomyolipoma volume associated with tuberous sclerosis complex in adult patients, VOTUBIA provides a substantial improvement in actual benefit (IAB III) in the treatment of patients not requiring immediate surgery (nephrectomy or embolisation). |
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
vQhZGs9xb4qmsdmA
